Dr Reddy's Laboratories reported a year-on-year decline in revenue to ₹81B for Q1FY27, falling short of analyst estimates of ₹88.05B and compared to ₹85.72B in the same period last year. The results were primarily impacted by a ₹2.40B charge from semaglutide API provisions and associated costs. The pharmaceutical major's EBITDA fell sharply to ₹8.6B versus ₹21.73B year-on-year, with margins contracting to 10.62% against 25.36% in the prior year period and well below the estimated 16%. Consolidated net profit came in at ₹4.44B compared to ₹14.1B year-on-year, against an estimate of ₹8.18B. Despite the reported decline, the company highlighted healthy double-digit growth in its base business, excluding the impact of lenalidomide and the specific API-related charges.

Excluding the semaglutide API impact, the company's financials showed stronger underlying performance, with an EBITDA margin of 15.4% and a profit before tax margin of 9.8%. The reported Return on Capital Employed (RoCE) stood at 5.3%, which would have been 8% excluding the API-related impact. Dr Reddy's maintained a net cash surplus of ₹3,058 Cr as of June 30, 2026. The EBITDA margin was further affected by higher solvent and freight costs arising from the Middle East conflict.

Financial Performance

The company's results missed analyst expectations across all key metrics, with revenue, EBITDA, and net profit all coming in below estimates. The following table summarises the reported performance against prior year figures and analyst estimates:

The company's revenue split revealed varied performance across geographies. North America revenue decreased 35% year-on-year to ₹2,205 Cr, attributed to lower lenalidomide sales, though base business growth remained positive. Emerging Markets grew 31% to ₹1,833 Cr, driven by new product launches and favourable foreign exchange rates. India revenue rose 17% to ₹1,718 Cr, supported by new brand launches and volume growth, while Europe increased 13% to ₹1,444 Cr aided by generics launches and forex tailwinds.

Business Highlights

Dr Reddy's achieved several strategic milestones during the quarter, including the first-to-market launch in the US of the anti-cancer drug bosutinib 400mg with 180-day exclusivity. The company became the first to launch a generic semaglutide injection for Type 2 Diabetes in Canada and introduced generic semaglutide tablets in India. Additionally, the nutrition offering Celevida GLP+ was launched through a collaboration with Nestlé.

The company received a Form 483 with seven observations following a Pre-Approval Inspection (PAI) at its biologics facility in Bachupally in June 2026, to which it responded within the stipulated timeline. Certain batches of semaglutide were found to be out of specification due to an issue associated with the API. On the sustainability front, Dr Reddy's celebrated 25 years of listing on the NYSE and was ranked in the top 1% globally by FTSE Russell.

Dr. Reddy's Laboratories Ltd. announced the appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, effective July 22, 2026. The Board of Directors approved this appointment pursuant to the recommendation of the Nomination, Governance and Compensation Committee. Additionally, the Board approved the appointment of M/s Deloitte Haskins & Sells LLP as the Independent Registered Public Accounting Firm for auditing financial statements to be included in the Annual Report on Form 20-F and reviewing interim financial statements filed with the U.S. Securities and Exchange Commission.

Management Appointments

Dr. Sridevi Khambhampaty has been inducted as a Member of the Management Council. She is an accomplished biopharmaceutical leader with over two decades of experience spanning Biologics R&D, Quality, and Business leadership. Most recently, she served as the CEO of Shilpa Biologics. Prior to this, she held senior leadership roles at Syngene International and Intas Biopharma. In her previous stint at Dr Reddy's, she led teams in Product Development and Quality Control at Biologics. She holds a PhD in Biological Sciences from NCBS (TIFR) and completed her postdoctoral research at Stanford University School of Medicine.

Auditor Appointment

The appointment of M/s Deloitte Haskins & Sells LLP as the Independent Registered Public Accounting Firm aligns with its earlier appointment as Statutory Auditors for a term of five consecutive years, commencing from the conclusion of the 42nd AGM till the conclusion of the 47th AGM, subject to shareholder approval. The firm, registered with the Institute of Chartered Accountants of India (Registration No. 117366W/W-100018), will audit financial statements for the Annual Report on Form 20-F and review interim financial statements filed with the U.S. Securities and Exchange Commission on Form 6-K.